Clinical Trial Update: Maternal Omega-3 Supplementation to Reduce Bronchopulmonary Dysplasia [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating maternal omega-3 supplementation to reduce bronchopulmonary dysplasia in newborns. The trial is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• Omega-3 Fatty Acid Supplement (omega-3 fatty acids)

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Bronchopulmonary Dysplasia, Child Development | Phase 3 | Status: ACTIVE_NOT_RECRUITING